Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3%

Affimed (NASDAQ:AFMD) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 742,900 shares, a decrease of 12.3% from the December 15th total of 846,900 shares. Approximately 5.7% of the shares of the stock are short sold. Based on an average trading volume of 291,200 shares, the days-to-cover ratio is currently 2.6 days.

Analyst Ratings Changes

A number of brokerages have weighed in on AFMD. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Affimed in a research note on Tuesday, December 10th. Wells Fargo & Company dropped their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Finally, Stifel Nicolaus dropped their target price on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AFMD. Choreo LLC bought a new stake in Affimed in the second quarter valued at about $54,000. Intellectus Partners LLC grew its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. FMR LLC increased its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the period. Finally, Jane Street Group LLC bought a new position in Affimed during the 3rd quarter worth approximately $44,000. 30.82% of the stock is currently owned by institutional investors.

Affimed Price Performance

Shares of AFMD stock opened at $1.08 on Friday. The firm’s 50 day moving average price is $2.10 and its two-hundred day moving average price is $3.40. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 52-week low of $1.03 and a 52-week high of $8.95.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.